Latest News

TSX:KNT 1 Year Share Price vs Fair Value Explore K92 Mining's Fair Values from the Community and select yours K92...

Key Insights Significant insider control over DiaMedica Therapeutics implies vested interests in company growth A total...

Bonterra Energy ( TSE:BNE ) Second Quarter 2025 Results Key Financial Results Revenue: CA$55.9m (down 10% from 2Q...

NYSE:VVX 1 Year Share Price vs Fair Value Explore V2X's Fair Values from the Community and select yours The V2X, Inc...

As the Canadian market navigates uncertainties surrounding potential rate cuts and inflation concerns, investors are keenly observing how these factors might influence various sectors. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential to offer surprising growth opportunities. While the term may seem outdated, these stocks can still provide significant returns when backed by strong financial health.

NZSE:MFT 1 Year Share Price vs Fair Value Explore Mainfreight's Fair Values from the Community and select yours Key...

NYSE:HZO 1 Year Share Price vs Fair Value Explore MarineMax's Fair Values from the Community and select yours Howard...

BMV:AC * 1 Year Share Price vs Fair Value Explore Arca Continental. de's Fair Values from the Community and select...

Microvast Holdings (MVST) recently announced its Q2 2025 earnings report, showing a growth in sales but a continued net loss. Despite a positive revenue outlook for the year, the company's share price fell 13% over the past week. This decline may be influenced by the broader market trend, where major indices like the Nasdaq slid due to a slump in tech stocks. Additionally, the appointment of an interim CFO amidst leadership transitions could have added uncertainty. The company's performance...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive catalyst. During this period, BioNTech also benefited from positive updates such as the European Medicines Agency's recommendation for its COVID-19 vaccine and the narrowing of net losses reported in Q2, reinforcing investor confidence. Meanwhile, broader market trends showed a general rise,...

Natera (NTRA) recently reported positive topline results from the IMvigor011 clinical trial, demonstrating significant improvements in disease-free and overall survival for patients, which may correlate with the company’s 16% share price rise over the past month. This announcement, paired with raised earnings guidance and the launch of the Fetal Focus NIPT, further supports the upbeat sentiment. Against a backdrop where major stock indices like the S&P 500 and Nasdaq have shown mixed...

First Solar (FSLR) recently saw its stock price surge by 31% over the last quarter. This impressive gain coincides with the announcement of a significant new supply agreement with 5N Plus Inc., highlighting plans to boost the production and delivery of key solar panel materials. Additionally, the company's updated guidance for 2025, which raises expectations for net sales and operating income, likely added confidence to investors. While the broader market showed mixed signals with the Dow...

Blackstone (BX) recently captured headlines with mounting speculation around its potential acquisition ventures, even as it posted a 17% rise in share price over the last quarter. The stalled €6 billion acquisition of Cognita Schools Limited may have posed uncertainties, yet the company's robust Q2 earnings report and continued investment endeavors seemingly strengthened investor confidence. While the Dow Jones rose to all-time highs amidst mixed market signals, Blackstone's diverse expansion...

Amcor (AMCR) recently announced a quarterly dividend of USD 0.13 per share and reported its Q4 2025 earnings results, showing substantial sales growth to USD 5,082 million, up from USD 3,535 million a year ago, but a transition from net income to a net loss of USD 39 million. Despite these earnings figures and steady dividend announcements, Amcor's share price recorded an 8.82% decline over the last quarter, which contrasts with the broader market's positive trend. Market uncertainties, such...

Brown & Brown (BRO) recently appointed Joia M. Johnson to its board of directors, a move likely aimed at strengthening the company's governance with her extensive legal and business experience. Last week, the company's share price remained largely flat, moving by only 0.37%. This performance aligns with broader market movements, considering that the Dow Jones touched an all-time high, while the S&P 500 and Nasdaq experienced declines. The appointment of Johnson and overall stability in the...

On August 15, 2025, AT&T (T) announced the election of Kelly J. Grier to its Board of Directors, marking a significant transition in its leadership team. Interestingly, this leadership transformation coincided with a recent 7% increase in the company’s share price over the past month. The broader market context showed mixed trends, with the Dow touching an all-time high but declines in tech-heavy indexes like the Nasdaq. Additionally, AT&T's positive earnings report, revealing increased...

Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking a significant enhancement in Alzheimer’s diagnostics. This breakthrough likely bolstered investor confidence, dovetailing with broader market trends that saw the Dow Jones reach new highs. Meanwhile, despite a generally mixed performance among major indices, the company's second-quarter earnings...

As the Dow Jones Industrial Average reaches new heights and the S&P 500 and Nasdaq experience declines amidst a tech slump, investors are closely monitoring Federal Reserve signals for potential rate cuts. In this climate of fluctuating indices and economic uncertainty, identifying stocks that may be undervalued can offer opportunities for those looking to capitalize on market inefficiencies.

As the Dow Jones Industrial Average reaches new heights and major indices experience fluctuations, investors are closely monitoring Federal Reserve signals and retail sector earnings for insights into future market movements. In this environment of uncertainty, stocks with high insider ownership can be particularly attractive as they often indicate strong confidence from those who know the company best.

As the U.S. market experiences fluctuations with major indices like the S&P 500 and Nasdaq sliding amidst a tech stock slump, investors are searching for opportunities that may not be as affected by these broader trends. Penny stocks, though often considered relics of past market eras, can still offer intriguing investment potential when backed by solid financials and growth prospects. In this article, we explore several penny stocks that exhibit financial strength and could present promising...

As the U.S. stock market navigates through a period of mixed performance with the Dow Jones Industrial Average reaching new highs while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in Federal Reserve policies that could impact future market dynamics. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as major indices fluctuate and economic indicators remain uncertain.

As the Dow Jones Industrial Average reaches new heights, contrasting with declines in the S&P 500 and Nasdaq due to Big Tech slumps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amidst mixed inflation signals. In this environment of fluctuating indices and economic uncertainty, dividend stocks can provide a measure of stability and income, making them an attractive option for those looking to navigate these volatile market conditions.

With a price-to-earnings (or "P/E") ratio of 28.5x The Williams Companies, Inc. ( NYSE:WMB ) may be sending very...

Key Insights Corvus Pharmaceuticals' estimated fair value is US$10.34 based on 2 Stage Free Cash Flow to Equity Current...